Foundation Fighting Blindness Files 13D on Opus Genetics
Ticker: IRD · Form: SC 13D · Filed: Oct 29, 2024 · CIK: 1228627
Sentiment: neutral
Topics: ownership-change, schedule-13d, pharmaceuticals
Related Tickers: OPUS
TL;DR
FFB just filed a 13D on OPUS. Big ownership change incoming.
AI Summary
Foundation Fighting Blindness, Inc. filed a Schedule 13D on October 29, 2024, regarding their ownership of Opus Genetics, Inc. The filing indicates a change in beneficial ownership, though specific details on the percentage or number of shares acquired or disposed of are not immediately clear from this header information. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and Rexahn Pharmaceuticals, Inc.
Why It Matters
This filing signals a significant change in the ownership structure of Opus Genetics, Inc., potentially impacting its stock price and strategic direction. Investors will be watching for further details on the nature of Foundation Fighting Blindness's stake.
Risk Assessment
Risk Level: medium — Schedule 13D filings often precede significant corporate actions or shifts in control, introducing uncertainty and potential volatility for the stock.
Key Players & Entities
- Foundation Fighting Blindness, Inc. (company) — Filing entity
- Opus Genetics, Inc. (company) — Subject company
- Ocuphire Pharma, Inc. (company) — Former name of subject company
- Rexahn Pharmaceuticals, Inc. (company) — Former name of subject company
FAQ
What is the specific percentage of Opus Genetics, Inc. shares beneficially owned by Foundation Fighting Blindness, Inc. after this filing?
The provided filing header does not specify the exact percentage or number of shares beneficially owned by Foundation Fighting Blindness, Inc.
When did Foundation Fighting Blindness, Inc. acquire or dispose of the shares triggering this 13D filing?
The filing date is October 29, 2024, and the date of the change in beneficial ownership is also listed as October 29, 2024, but the specific transaction date is not detailed in the header.
What was the previous name of Opus Genetics, Inc. that is relevant to this filing?
Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and prior to that, Rexahn Pharmaceuticals, Inc.
What is the primary business of Opus Genetics, Inc. according to the SIC code?
Opus Genetics, Inc. is classified under the SIC code 2834, which corresponds to Pharmaceutical Preparations.
Where is the principal business address for Opus Genetics, Inc.?
The principal business address for Opus Genetics, Inc. is 37000 GRAND RIVER AVE., SUITE 120, FARMINGTON HILLS, MI 48335.
Filing Stats: 3,692 words · 15 min read · ~12 pages · Grade level 16.2 · Accepted 2024-10-29 17:26:27
Key Financial Figures
- $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o
- $0.00001 — ts of 2,564,752 shares of common stock, $0.00001 par value per share (the Common Stock)
- $26.00 — cumulative quarterly cash dividends of $26.00 per share of Preferred Stock; provided
- $15.26 — vidend due on October 15, 2025 shall be $15.26. Any such dividends will be payable qua
Filing Documents
- d856407dsc13d.htm (SC 13D) — 93KB
- 0001193125-24-246646.txt ( ) — 95KB
From the Filing
SC 13D 1 d856407dsc13d.htm SC 13D SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. __)* Opus Genetics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 67577R102 (CUSIP Number) Russell Kelley, Managing Director Foundation Fighting Blindness Retinal Degeneration Fund 223 S. West Street, Suite 900 Raleigh, NC 27603 (919) 610-2064 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) October 22, 2024 (Date of Event which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosure provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 67577R102 1 NAME OF REPORTING PERSONS Foundation Fighting Blindness Retinal Degeneration Fund 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)(b) 3 SEC USE ONLY 4 SOURCE OF FUNDS OO 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 0 8 SHARED VOTING POWER 2,564,752 (1) 9 SOLE DISPOSITIVE POWER 0 10 SHARED DISPOSITIVE POWER 2,564,752 (1) 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,564,752 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.16% (2) 14 TYPE OF REPORTING PERSON CO, OO (1) Consists of 2,564,752 shares of common stock, $0.00001 par value per share (the Common Stock) of Opus Genetics Inc., a Delaware Corporation (the Issuer). Does not include 6,927.419 shares of Series A non-voting convertible preferred stock, $0.0001 par value per share (the Preferred Stock). Contingent upon and following the requisite stockholder approval of the conversion of the Preferred Stock, each share of Preferred Stock will automatically convert into 1,000 shares of Common Stock. (2) This percentage is based on 31,435,507 shares of Common Stock outstanding as of October 22, 2024, as disclosed by the Issuer to the Reporting Persons. CUSIP No. 67577R102 1 NAME OF REPORTING PERSONS Foundation Fighting Blindness, Inc. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)(b) 3 SEC USE ONLY 4 SOURCE OF FUNDS OO 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Maryland NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 0 8 SHARED VOTING POWER 2,564,752 ( 3 ) 9 SOLE DISPOSITIVE POWER 0 10 SHARED DISPOSITIVE POWER 2,564,752 (3) 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,564,752 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.16% ( 4 ) 14 TYPE OF REPORTING PERSON CO (3 ) Consists of 2,564,752 shares of Common Stock of the Issuer. Does not include 6,927.419 Preferred Stock. Contingent upon and following the requisite stockholder approval of the conversion of the Preferred Stock, each share of Preferred Stock will automatically convert into 1,000 shares of Common Stock. (4 ) This percentage is based on 31,435,507 shares of Common Stock outstanding as of October 22, 2024, as disclosed by the Issuer to the Reporting Persons. SCHEDULE 13D Item1. Security and Issuer. This statement on Schedule 13D relates to the shares of Common Stock of the Issuer. The Issuers principal executive office is located at 37000 Grand River Avenue, Suite 120 Farmington Hills, Michigan. Item2. Identity and Background (a) This Schedule 13D is being filed pursuant to Rule 13d-1 of Regulations 13D-G under the Securities Exchange Act of 1934 (the Act) on behalf of Foundation Fighting Blindness Retinal Degeneration Fund, a